Subject: Research Agreement between the University of Michigan and Ascentage Pharma Group Corporation, Ltd.

Action Requested: Authorization to enter into Agreement

Preamble:

A statutory conflict of interest situation was identified by the Office of Research and Sponsored Projects while reviewing the Proposal Approval Form which then triggered a review by the Medical School Conflict of Interest Board. A plan for management of the possible risks associated with the conflict of interest was then developed and approved by the Board and agreed to by the parties involved.

This proposed research agreement (“Agreement”) falls under the State of Michigan Conflict of Interest Statute because Professor Shaomeng Wang is an employee of the University of Michigan (“University”), and a partial owner of Ascentage Pharma Group Corporation, Ltd. The law permits such an Agreement provided it is disclosed to the Board of Regents (“Regents”) of the University of Michigan and approved in advance by a 2/3 vote.

Background:

Shaomeng Wang, PhD, a Professor in the Department of Internal Medicine – Hematology/Oncology, is the partial owner of a for-profit company called Ascentage Pharma Group Corporation, Ltd. (the “Company”). The Company wishes to fund a project entitled “MDM2-p53 Inhibitor APG-115 and Tumor Immunity” (ORSP #18-PAF01409) in the Department of Surgery under the direction of Dr. Weiping Zou. The purpose of this project is to evaluate the role of APG-115 inhibitor in tumor ferroptosis, spontaneous tumor immunity, conventional therapy-induced tumor immunity, and blockade-induced tumor immunity.

Agreement Terms:

The terms of the Agreement conform to University policy. The period of performance for the project is approximately two (2) years. The amount of funding support will not exceed $583,625. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Impact of the Agreement:

The Agreement will support an effort by Dr. Zou to use his expertise and University laboratory, as well as other University resources, to generate important information regarding the mechanism of action and efficacy of a novel tumor inhibitor for the prevention and treatment of melanoma, colon cancer, and ovarian cancer.
Recommendations:

This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into this Agreement with Ascentage Pharma Group Corporation, Ltd.

Respectfully submitted,

S. Jack Hu
Vice President for Research

February 2018